Pharmacological management of metastatic boney pain

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 7, 2004, Pages 1555-1563

  Viney, Richard P C ^b   Hayne, Dickon ^c   Ayra, Manit ^d   Patel, Hitendra R H ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b University Hospital   (United Kingdom)

^c SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Bone metastatis; Breast; Cancer; Pain; Prostate

Indexed keywords

ALENDRONIC ACID; AMITRIPTYLINE; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBAMAZEPINE; CLODRONIC ACID; CODEINE; DIAMORPHINE; DIHYDROCODEINE; ETIDRONIC ACID; FENTANYL; HYDROMORPHONE; IBANDRONIC ACID; INCADRONIC ACID; LAXATIVE; METHADONE; MINODRONIC ACID; MORPHINE; NERIDRONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OLPADRONIC ACID; OPIATE; OXYCODONE; PAMIDRONIC ACID; PARACETAMOL; RISEDRONIC ACID; TILUDRONIC ACID; UNINDEXED DRUG; VALPROIC ACID; ZOLEDRONIC ACID;

ANALGESIA; BONE METASTASIS; BONE PAIN; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONSTIPATION; CONTROLLED DRUG RELEASE; DRUG COST; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FRACTURE; HALLUCINATION; HUMAN; NAUSEA; NEUROPATHIC PAIN; PATIENT COMPLIANCE; PREVALENCE; QUALITY OF LIFE; RESPIRATION DEPRESSION; REVIEW; SEDATION; STRUCTURE ACTIVITY RELATION; VOMITING;

BONE NEOPLASMS; CLINICAL TRIALS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; GUIDELINES; HOLISTIC HEALTH; HUMANS; INTERPROFESSIONAL RELATIONS; PAIN; WORLD HEALTH ORGANIZATION;

EID: 3543147875     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.7.1555     Document Type: Review

References (39)

1. WEISS SC, EMANUEL LL, FAIRCLOUGH DL, EMANUEL EJ: Understanding the experience of pain in terminally ill patients. Lancet (2001) 357(9265):1311-1315.
2. WORLD HEALTH ORGANISATION: Cancer Pain Relief, with a guide to opioid availability (2nd edn). Geneva: World Health Organisation, 1996.
3. COLEMAN R: New roles for bisphosphonates in cancer therapy. Progress Palliat. Care (1996) 4:39-43.
4. EXPERT WORKING GROUP OF THE EUROPEAN ASSOCIATION FOR PALLIATIVE CARE: Morphine in cancer pain: modes of administration. Br. Med. J. (1996) 12:823-826.
5. MIASKOWSKI C, MACK KA, DODD M et al.: Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. J. Pain (2002) 3(1):12-20.
6. SCHOLES C, TROTMAN I: The theoretical basis of opioid rotation. CME Bull. Palliat. Med. (1998) 1:1.
7. FALLON M: Opioid rotation: does it have a role? Palliat. Med. (1997) 11:177-178.
8. TWYCROSS R, WILCOCK A, THORP S: The Palliative Care Formulary. Radcliffe Medical Press, Oxford, UK (1998).
9. MCDONALD CJ, MILLER AJ: A comparative potency study of a controlled release tablet formulation of hydromorphone with controlled release morphine in patients with cancer pain. Abstracts of the Fifth Congress. Eur. J. Palliat. Care. (1997).
10. DE STOUTZ ND, BRUERA E, SUAREZ-ALMAZOR M: Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage. (1995) 10:378-384.
11. RIPAMONTI C, ZECCA E, BRUERA E: An update on the clinical use of methadone for cancer pain. Pain (1997) 70:109-115.
12. LIPTON A: Bisphosphonates and breast carcinoma. Cancer (1997) 80(Suppl. 8):1668-1673.
13. SAAD F, GLEASON DM, MURRAY R et al., ZOLEDRONIC ACID PROSTATE CANCER STUDY GROUP: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. (2002) 94(19):1458-1468.
14. ADAMI S: Bisphosphonates in prostate cancer. Cancer (1997) 80(Suppl. 8):1674-1679.
15. URAL AU, YILMAZ MI, AVCU F et al.: The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. Int. J. Hematol. (2003) 78(5):443-449.
16. HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N. Engl. J. Med. (1996) 335(24):1836-1837.
17. ROSEN LS, GORDON D, TCHEKMEDYIAN S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J. Clin. Oncol. (2003) 21(16):3150-3157.
18. GLOVER D, LIPTON A, KELLER A et al.: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer (1994) 74(11):2949-2955.
19. TUBIANA-HULIN M, BEUZEBOC P, MAURIAC L et al.: [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases] Bull. Cancer (2001) 88(7):701-707.
20. KYLMALA T, TAMMELA TL, LINDHOLM TS, SEPPANEN J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Gynaecol. (1994) 83(4):316-319.
21. VITALE G, FONDERICO F, MARTIGNETTI A et al.: Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br. J. Cancer (2001) 84(12):1586-1590.
22. RICHARDS MA: Advanced breast cancer: use of resources and cost implications. Br. J. Cancer (1993) 67:856-860.
23. ROEMER-BECUWE C, VIGANO A, ROMANO F et al.: Safety of subcutaneous clodronate and efficacy in hypercalcaemia of malignancy: a novel route of administration. J. Pain Symptom Manage. (2003) 26(3):843-848.
24. FRANCIS MD, RUSSELL RG, FLEISCH H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 165:1264-1266.
25. FLEISCH H, RUSSELL RG, FRANCIS MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 165:1262-1264.
26. SAHNI M, GUENTHER HL, FLEISCH H, COLLIN P, MARTIN TJ: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J. Clin. Invest. (1993) 91:2004-2011.
27. HUGHES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner. Res. (1995) 10:1478-1487.
28. FRITH JC, MONKKONEN J, BLACKBURN GM, RUSSELL RG, ROGERS MJ: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichlormethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. (1997) 12:1358-1367.
29. LUCKMAN SP, HUGHES DE, COXON FP et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13:581-589.
30. REED SD, RADEVA JI, GLENDENNING GA, SAAD F, SCHULMAN KA: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J. Urol. (2004) 171(4):1537-1542.
31. NHS EXECUTIVE: EL(96)85. A Policy Framework For Commissioning Cancer Services: Palliative Care Services. October (1996).
32. ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN: Pharmaceutical care of cancer patients in the community. Pharm. J. (1997) 258:54-57.
33. CALMAN K, HINE J: A Policy Framework for Commissioning Cancer Services. Department of Health. April (1995).
34. MUNDY GR: Mechanisms of bone metastasis. Cancer (1997) 80:1546-1556.
35. GOLTZMEN D: Mechanisms of the development of osteoblastic metastases. Cancer (1997) 80:1581-1587.
36. SATOR O: Radioisotopic treatment of bone pain from metastatic prostate cancer. Curr. Oncol. Rep. (2003) 5(3):258-262.
37. URCH CE, DONOVAN-RODRIGUEZ T, DICKENSON AH: Alterations in dorsal horn neurones in a rat model of cancer induced bone pain. Pain (2003) 106(3):347-356.
38. CLOHISY DR, MANTYH PW: Bone cancer pain. Clin. Orthop. (2003) 415(Suppl.):S279-S288.
39. MATA M, GLORIOSO J, FINK DJ: Development of HSV-mediated gene transfer for the treatment of chronic pain. Exp. Neurol. (2003) 184(Suppl. 1):S25-S29.